Posts

Posted on

Sapiens Acquires Candela to Expand its Footprint in APAC and Enhance its Life Product Portfolio

PR Newswire

A Strategic Move to Strengthen Sapiens’ Position in the APAC Market and Strengthen our Life Position Globally


ROCHELLE PARK, N.J.
, April 22, 2025 /PRNewswire/ — Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a global leader in intelligent insurance software solutions today announced the acquisition of Candela, a leading intelligent automation company servicing blue-chip, APAC-based insurance clients. This strategic move aims to enhance Sapiens’ life product portfolio and expand its presence in the APAC region. The transaction is subject to customary closing conditions and expected to close during the second quarter of 2025.

Sapiens_Logo

Candela offers an end-to-end insurance automation platform along with digital services and solutions. Candela has 23 customers, primarily in Singapore, Malaysia, Thailand, Hong Kong and South Africa. The Candela team of over 100 employees is mainly in Bangalore, India. Candela is currently part of Azentio, a Singapore-based company.

With nearly 30 years of deep industry expertise, Candela is well-positioned to support Sapiens’ vision and strategy for growth in the APAC market in addition to providing innovative new capabilities to Sapiens global customers. Candela’s solutions are complementary to Sapiens Insurance Platform and Policy Administration Systems for Life. By leveraging Candela’s Business Process Modelling (BPM) and Case Management capabilities, Sapiens aims to enhance its Insurance Platform for life offerings.

This acquisition also enables the implementation of standardized processes over external legacy solutions, ensuring a consistent and enhanced experience for agents, customers, and administrators.

“I am pleased to welcome the Candela team and customers as part of our strategy to continue to expand our presence in the APAC region and enhance our sophisticated life insurance platform” said Roni Al-Dor, CEO and President at Sapiens. “We will continue to support Candela’s customers and products, increasing value across the entire insurance lifecycle and supporting insurers’ digital transformations with a comprehensive product proposition and a diverse range of service capabilities.”

“Joining the Sapiens organization opens up a wealth of resources and a global network of relationships for the Candela team and our clients,” said Amitabh Poddar, Business Head, Candela. “Integrating our intelligent automation solutions into Sapiens’ leading insurance software platform will enhance our capabilities and provide even greater value to our customers. We are committed to ensuring a smooth transition and maintaining uninterrupted service for all our clients.”

The acquisition of Candela is structured as a cash transaction. Candela non-GAAP full year 2024 revenues were $8 million USD. Sapiens will pay an aggregate cash consideration of $22 Million dollar. The acquisition will be accretive to profit starting from the fourth quarter of 2025.   The transaction is expected to be completed during the second quarter of 2025. Upon completion, Candela will become wholly owned by Sapiens.

About Sapiens

Sapiens International Corporation (NASDAQ and TASE: SPNS) is a global leader in intelligent insurance SaaS software solutions. With Sapiens’ robust platform, customer-driven partnerships, and rich ecosystem, insurers are empowered to future-proof their organizations with operational excellence in a rapidly changing marketplace. Our SaaS based solutions help insurers harness the power of AI and advanced automation to support core solutions for property and casualty, workers’ compensation, and life insurance, including reinsurance, financial & compliance, data & analytics, digital, and decision management. Sapiens boasts a longtime global presence, serving over 600 customers in more than 30 countries with its innovative offerings. Recognized by industry experts and selected for the Microsoft Top 100 Partner program, Sapiens is committed to partnering with our customers for their entire transformation journey and is continuously innovating to ensure their success.   For more information visit https://sapiens.com or follow us on LinkedIn.

About Candela

Candela Labs is an IP-led technology focused on smart automation and digital solutions for insurers. We work on the cutting edge of InsureTech/FinTech, creating products and point solutions in our IP Labs that enable our clients to truly transform themselves for enriched digital adoption, enhanced customer & channel experience and exceptional operational efficiency.

About Azentio

Azentio Software incorporated in 2020 at Singapore, has been carved out of 3i Infotech, Candela Labs, Beyontec Technologies and Path Solutions. Azentio Software provides mission critical, vertical-specific software products for customers in banking, financial services and insurance verticals. Azentio has over 800 customers in more than 60 countries, with a team of over 2,300 employees across offices in 12 countries (and growing) globally and is wholly owned by Funds advised by Apax Partners. Visit: https://www.azentio.com/

Investor and Media Contact 
Yaffa Cohen-Ifrah 
Sapiens Chief Marketing Officer and Head of Investor Relations
Email: [email protected] 

Forward Looking Statements 

Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; the global macroeconomic environment, including headwinds caused by inflation, relatively high interest rates, potentially unfavorable currency exchange rate movements, and uncertain economic conditions, and their impact on our revenues, profitability and cash flows; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the coronavirus epidemic, and fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2024, to be filed in the near future, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/sapiens-acquires-candela-to-expand-its-footprint-in-apac-and-enhance-its-life-product-portfolio-302434112.html

SOURCE Sapiens International Corporation

Posted on

Gaotu Techedu Announces Changes in Board and Committee Composition

PR Newswire


BEIJING
, April 22, 2025 /PRNewswire/ — Gaotu Techedu Inc. (NYSE: GOTU) (“Gaotu” or the “Company”), a technology-driven education company and online large-class tutoring service provider in China, today announced that Mr. Ming Liao has tendered his resignation as an independent director of the Company for personal reasons, effective on April 22, 2025. Mr. Ming Liao also stepped down as a member of the audit committee and the compensation committee, and the chair of nominating and corporate governance committee on the same date. The resignation of Mr. Ming Liao does not result from any dispute or disagreement with the Company.

The Company further announced the appointment of Mr. Hao Sun as a new independent director, a member of the audit committee and the compensation committee, and the chair of nominating and corporate governance committee of the Board, effective on April 22, 2025. The Board has determined that Mr. Hao Sun satisfies the independence requirements under Section 303A of the Corporate Governance Rules of the New York Stock Exchange and Rule 10A-3 of the Exchange Act.

Mr. Hao Sun has been a Tenured Associate Professor in the Gaoling School of Artificial Intelligence at Renmin University of China since September 2021. Previously, Mr. Sun held Tenure-Track Assistant Professor positions at the Northeastern University, Boston from 2018 to 2021, and at the University of Pittsburgh from 2017 to 2018. Mr. Sun received his bachelor’s degree in civil engineering from Hohai University in 2010, his master’s and Ph.D. degrees in engineering mechanics from Columbia University in 2011 and 2014, respectively, and completed his postdoctoral training at MIT during 2014 to 2017. Mr. Sun’s research focuses on interdisciplinary AI with applications spanning science, engineering, and education. Mr. Sun has authored 80 peer-reviewed publications in top-tier journals such as Nature Machine Intelligence and Nature Communications, as well as leading AI conferences including ICLR, NeurIPS, and KDD. Mr. Sun has received multiple awards including Forbes “30 Under 30”: Science in 2018, MIT Technology Review Intelligent Computing Innovator Award of China in 2022, and AI100 Innovators: Young Pioneers in AI of China in 2025.

The Company extends its sincere gratitude for Mr. Ming Liao’s dedication and invaluable contributions and wishes him all the best in his future endeavors. At the same time, the Company is pleased to welcome Mr. Hao Sun to the Board.


Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s ability to continue to attract students to enroll in its courses; the Company’s ability to continue to recruit, train and retain qualified teachers; the Company’s ability to improve the content of its existing course offerings and to develop new courses; the Company’s ability to maintain and enhance its brand; the Company’s ability to maintain and continue to improve its teaching results; and the Company’s ability to compete effectively against its competitors. Further information regarding these and other risks is included in the Company’s reports filed with, or furnished to the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no duty to update such information or any forward-looking statement, except as required under applicable law.

About Gaotu Techedu Inc.

Gaotu is a technology-driven education company and online large-class tutoring service provider in China. The Company offers learning services and educational content & digitalized learning products. Gaotu adopts an online live large-class format to deliver its courses, which the Company believes is the most effective and scalable model to disseminate scarce high-quality teaching resources to aspiring students in China. Big data analytics permeates every aspect of the Company’s business and facilitates the application of the latest technology to improve teaching delivery, student learning experience, and operational efficiency.

For further information, please contact:

Gaotu Techedu Inc.
Investor Relations
E-mail: [email protected]

Piacente Financial Communications
Brandi Piacente
Tel: +1 212 481-2050
Jenny Cai
Tel: +86 10 6508-0677
Email: [email protected] 

Cision View original content:https://www.prnewswire.com/news-releases/gaotu-techedu-announces-changes-in-board-and-committee-composition-302434005.html

SOURCE Gaotu Techedu Inc.

Posted on

IFF Pharma Solutions to Showcase Plant-Based Dietary Supplement Ingredients and Technical Expertise at Vitafoods™ Europe 2025

IFF Pharma Solutions to Showcase Plant-Based Dietary Supplement Ingredients and Technical Expertise at Vitafoods™ Europe 2025

Improving the World of Dietary Supplements with a Breadth of Proven Brands.

NEW YORK–(BUSINESS WIRE)–
IFF (NYSE: IFF) Pharma Solutions is excited to announce its participation at Vitafoods™ Europe 2025, the premier global nutraceutical event. The team will showcase its cutting-edge dietary supplement plant-based ingredients portfolio of innovative and trusted brands including SeaGel®, VERDIGEL™ SC, GRINDSTED® Pectin Premium, Ac-Di-Sol®, Avicel®, Accelerate®, and METHOCEL™ in hall 4 at booth 4F25, May 20-22, at the Fira Barcelona Gran Via.

“We are excited to highlight vivid examples of how our high-quality functional ingredients and technical expertise help our customers produce superior supplements,” said Firat Nalbantoglu, EMEA commercial leader, IFF Pharma Solutions. “Our technical and commercial experts look forward to offering solutions for formulation and processing challenges. If you aim to enhance efficacy and bioavailability in your dietary supplements, we invite you to discover new possibilities with us.”

IFF Pharma Solutions is committed to advancing the dietary supplement industry with its portfolio of high-performance ingredients, offering plant-based solutions and vegan alternatives, as well as reliable technologies for immediate and controlled release:

  • SeaGel® and VERDIGEL™ SC: These plant-based alternatives to gelatin offer clean-label, non-GMO solutions for superior quality and high performance vegan softgels.
  • GRINDSTED® Pectin Premium: A renowned, citrus-sourced ingredient for plant-based gummies that delivers an excellent consumer experience.
  • Avicel®: A cellulose-based tablet binder and filler, Avicel® ensures the production of small, high-quality tablets with low-dusting and efficient tableting processes. Avicel® acts as a suspending agent, enhancing the stability and efficacy of liquid formulations.
  • Ac-Di-Sol®: A non-GMO cellulose-based tablet disintegrant that delivers nutritional ingredients faster.
  • METHOCEL™: A versatile cellulose-based solution for vegetarian hard capsules and controlled-release tablet matrices – resistant to heat and humidity conditions.
  • Accelerate®: A cellulose-based super disintegrant for immediate release.

Visit here to learn more about IFF Pharma Solutions.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Britta Meys

Global Communications Lead EMEA

+49 151 14486359

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Retail Health Specialty General Health Vitamins/Supplements Food/Beverage

MEDIA:

Logo
Logo
Posted on

SINOVAC Management Statement Regarding Auditor Resignation

Beijing, April 22, 2025 (GLOBE NEWSWIRE) — To the Shareholders of Sinovac Biotech Ltd. and Other Stakeholders:

The management of Sinovac Biotech Ltd. (NASDAQ: SVA, “SINOVAC” or the “Company”) recently received notice of its external auditor’s decision to resign from its engagement for the Company’s year-end audit for the fiscal year 2024.

According to the resignation letter, the auditor’s decision was prompted by an announcement the Company’s current Board made on April 1, 2025, stating that “the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office.”  The auditor expressed concern that such a review introduces uncertainty regarding the factual and legal basis upon which its audit opinion would rely.  As a result of the resignation, the Company will not be able to meet the deadline to file its Form 20-F annual report with the U.S. Securities and Exchange Commission (“SEC”), which is due by April 30, 2025.

This development is deeply concerning, as it reflects that the actions taken by the current Board have caused disruption to the Company’s compliant operations and governance. The Board’s stated justification for initiating this review appears to be based on a January 16, 2025 ruling by the UK Privy Council. That ruling held, among other things, that the slate of directors nominated by a group of shareholders at the Company’s 2018 Annual General Meeting had been validly appointed. However, the current composition of the Board does not reflect that slate.  Of the five directors recently disclosed, only three were part of that slate, and one of those three is currently in custody following a conviction of crimes of embezzlement, forgery of government documents and seals, and forgery of company seals. Multiple shareholders have raised serious concerns regarding the current Board’s qualifications, legitimacy and its authority to act as the Company’s Board.

While we respect the ruling of the UK Privy Council, we, as the Company’s management, believe that maintaining the stability and orderly operation of the Company is in the best interests of all shareholders and stakeholders.  While the Privy Council’s decision validated the slate of directors nominated by certain shareholders at the Company’s 2018 Annual General Meeting, it did not set aside any corporate actions taken by the former board since February 2018.

In fact, it was under the leadership of the former board that SINOVAC achieved tremendous growth, expanded into multiple international markets, and significantly increased both revenue and shareholder value. The management team supports the distribution of cash dividends to shareholders, which would not have been possible without the initiatives and achievements of the former board.  Any attempt to unravel or reverse corporate actions taken by the former board would not only create operational chaos and legal uncertainty but would also undermine the Company’s future growth.  The auditor’s resignation and the resulting delay of the Form 20-F filing are unfortunate illustrations of the damage such instability can cause.

At this critical juncture, given the potential concerns regarding the qualifications of certain current Board members and the procedures by which they were appointed, as well as the disruptive impact caused by their recent actions, for the Company’s continued operations and long-term stability, we call on all shareholders for cooperation, coordination, and a forward-looking perspective.  We believe a shareholder meeting should be held as soon as practicable to elect a new Board that can provide the strong, stable, and legitimate leadership SINOVAC needs to move forward.  In the meantime, we also call for and support the prompt reinstatement of normal trading of the Company’s shares.

As the management team of a publicly traded company, we have a fiduciary duty to act in the best interests of all shareholders.  In light of recent developments, we believe it is our responsibility to issue this public statement to ensure transparency and to keep shareholders and stakeholders fully informed of these important matters.

We remain committed to serving the long-term interests of SINOVAC and all its shareholders. For the Company’s compliant operations and governance, we will actively facilitate the engagement of a new independent registered public accounting firm.

– Management of SINOVAC

April 22, 2025, Beijing

 



Management of SINOVAC
Sinovac Holding Group Co., Ltd.
+86(010)82799800
[email protected]

Posted on

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit

PR Newswire


NEW YORK
, April 21, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important May 12, 2025 lead plaintiff deadline.

So what: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Geron class action, go to https://rosenlegal.com/submit-form/?case_id=36747 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) despite contrary representations to investors, a lack of awareness of RYTELO among health care providers, the weekly monitoring requirement, and seasonality and existing competition would impair Geron’s ability to capitalize on the purportedly significant unmet need for the drug; (2) accordingly, the RYTELO launch was unlikely to be as profitable as Geron had led investors to believe; (3) as a result, Geron’s business and/or financial prospects were overstated; and (4) as a result, Geron’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Geron class action, go to https://rosenlegal.com/submit-form/?case_id=36747 or https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gern-investors-have-opportunity-to-lead-geron-corporation-securities-fraud-lawsuit-302433785.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

SANMINA CORPORATION INVITES YOU TO JOIN ITS SECOND QUARTER FISCAL 2025 EARNINGS CONFERENCE CALL

PR Newswire


SAN JOSE, Calif.
, April 21, 2025 /PRNewswire/ — Sanmina Corporation (NASDAQ: SANM) announced today that it will host its second quarter fiscal 2025 earnings conference call on Monday, April 28, 2025 at 5:00 PM ET.

The live webcast presentation and supporting materials will be available on the Sanmina website at www.sanmina.com in the Investor Relations section. A webcast replay will be available at the same location upon the conclusion of the event.

About Sanmina
Sanmina Corporation, a Fortune 500 company, is a leading integrated manufacturing solutions provider serving the fastest growing segments of the global Electronics Manufacturing Services (EMS) market. Recognized as a technology leader, Sanmina provides end-to-end manufacturing solutions, delivering superior quality and support to Original Equipment Manufacturers (OEMs) primarily in the industrial, medical, defense and aerospace, automotive, communications networks and cloud infrastructure markets. Sanmina has facilities strategically located in key regions throughout the world. More information about the Company is available at www.sanmina.com.

Sanmina Contact:

Paige Melching

SVP, Investor Communications
408.964.3610

Logo – https://mma.prnewswire.com/media/10544/SANMINA_CORPORATION_LOGO.jpg

Cision View original content:https://www.prnewswire.com/news-releases/sanmina-corporation-invites-you-to-join-its-second-quarter-fiscal-2025-earnings-conference-call-302433838.html

SOURCE Sanmina Corporation

Posted on

BlackRock Health Sciences Term Trust (BMEZ) Announces Final Results of Tender Offer

BlackRock Health Sciences Term Trust (BMEZ) Announces Final Results of Tender Offer

NEW YORK–(BUSINESS WIRE)–
BlackRock Health Sciences Term Trust (the “Fund”) announced today the final results of the Fund’s tender offer (the “Tender Offer”) for up to 40% of its outstanding common shares (the “Shares”), which expired on April 17, 2025.

The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made within approximately five business days after the expiration date (anticipated to be April 25, 2025).

The final results of the Tender Offer are provided in the table below:

Fund Name

Ticker

CUSIP

Number of

Shares

Offered for Repurchase

Number of

Tendered Shares

to be Purchased

Purchase

Price*

BlackRock Health Sciences

Term Trust

BMEZ

09260E105

40,502,046

38,753,713

14.2086

*Equal to 99.5% of the Fund’s net asset value per Share as of the close of regular trading on the New York Stock Exchange on April 21, 2025 (the business day immediately following the expiration date of the Tender Offer).

Important Notice

This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund’s common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission (“SEC”) as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Fund.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

Availability of Fund Updates

BlackRock will update performance and certain other data for the Fund on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund’s net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Fund with the SEC are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Fund. The information contained on BlackRock’s website is not a part of this press release.

1-800-882-0052

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

TOTAL RETURN SECURITIES FUND PORTFOLIO SNAPSHOT

PR Newswire


NEW YORK
, April 21, 2025 /PRNewswire/ — As previously announced, on February 21, 2025, stockholders of Total Return Securities Fund (f/k/a The Swiss Helvetia Fund, Inc.) (the “Fund”) (NYSE: SWZ) approved the following: (1) an investment advisory agreement between the Fund and Bulldog Investors, LLP (which was effective on March 31, 2025); (2) replacement of the Fund’s fundamental investment objective of capital appreciation by investing in equity and equity-linked securities of Swiss companies with a non-fundamental investment objective of providing long-term total return; and (3) changes to the Fund’s fundamental investment restrictions in order to expand the types of investments the Fund can make to meet its new investment objective. Also, as previously announced, the Fund’s Board of Directors subsequently authorized (1) the sale of substantially all of the Fund’s portfolio securities, and (2) a special cash distribution (consisting substantially or entirely of long-term capital gains) of $3.00 per share on April 14, 2025 to record holders as of April 3, 2025.

In response to requests from several shareholders to provide information about the Fund’s current portfolio, the Fund has elected to provide the following breakdown of its portfolio as of Thursday, April 17, 2025.

Swiss Public Securities = 31.4%
Swiss Non-Public Securities = 2.1%
U.S. Public Securities = 7.5%
Cash and Cash Equivalents = 59.0%

Total Net Assets = $90.4 million

Contact: Thomas Antonucci, 201-881-7102, [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/total-return-securities-fund-portfolio-snapshot-302433830.html

SOURCE Total Return Securities Fund

Posted on

UCTT Investors Have Opportunity to Lead Ultra Clean Holdings, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, April 21, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) between May 6, 2024 to February 24, 2025, both dates inclusive (the “Class Period”), of the important May 23, 2025 lead plaintiff deadline.

So what: If you purchased Ultra Clean securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Ultra Clean class action, go to https://rosenlegal.com/submit-form/?case_id=37386 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 23, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants created the false impression that they possessed reliable information pertaining to the demand for Ultra Clean’s products and services in the domestic Chinese market. In truth, Ultra Clean’s optimistic reports of significant growth and increased earnings potential fell short of reality as they failed to incorporate the impending weaker demand due to issues one of its major customers was facing, extended qualification timelines, and inventory absorption, particularly given the volatility of the semiconductor industry. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ultra Clean class action, go to https://rosenlegal.com/submit-form/?case_id=37386 or https://rosenlegal.com/submit-form/?case_id=28116 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/uctt-investors-have-opportunity-to-lead-ultra-clean-holdings-inc-securities-fraud-lawsuit-302433734.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

TMCI Investors with Losses in Excess of $100K Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, April 21, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025.

So What: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Treace Medical class action, go to https://rosenlegal.com/submit-form/?case_id=38284 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the “Lapiplasty”); (2) as a result, Treace Medical’s revenue declined and Treace Medical needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about Treace Medical’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Treace Medical class action, go to https://rosenlegal.com/submit-form/?case_id=38284 https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tmci-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-treace-medical-concepts-inc-securities-fraud-lawsuit-302433731.html

SOURCE THE ROSEN LAW FIRM, P. A.